ADMA BIOLOGICS, INC. (ADMA) Q3 2025 10-Q Quarterly Report
Filed: Nov 5, 2025Period ending Sep 30, 2025
Health Care
Biological Products, (No Diagnostic Substances)SEC EDGAR ADMA BIOLOGICS, INC. (ADMA) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 5, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.
ADMA BIOLOGICS, INC. Q3 2025 10-Q Analysis
Risk Factors
- • New risk: FDA approval of yield enhancement production process in April 2025 may impact revenue forecasts and operational scaling
- • Most updated risk: Net income of $197.7M in 2024 vs prior losses, with increased operating expenses due to commercialization and R&D expansion
ADMA BIOLOGICS, INC. Q3 2025 Quarterly FinancialsXBRL
Revenue
$134M
▲ +12.0% YoY▲ +10.0% QoQ
Net Income
$36M
▲ +1.4% YoY▲ +6.5% QoQ
Gross Margin
56.3%
▲ +656bp YoY▲ +123bp QoQ
Operating Margin
38.0%
▲ +493bp YoY▲ +292bp QoQ
Net Margin
27.1%
▼ -282bp YoY▼ -91bp QoQ
ROE
8.4%
Total Assets
$569M
EPS (Diluted)
$0.15
▲ +7.1% YoY▲ +7.1% QoQ
Operating Cash Flow
$13M
▼ -46.9% YoY▼ -37.1% QoQ
Source: XBRL data from ADMA BIOLOGICS, INC. Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.
Get deeper insights on ADMA BIOLOGICS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.